Weekly Endocrinology Research Analysis
This week’s endocrinology literature highlights rapid therapeutic and precision-medicine advances: a phase 2b trial demonstrates clinically meaningful glycaemic lowering with a once-daily oral small-molecule GLP‑1 receptor agonist (elecoglipron), potentially expanding GLP‑1 access beyond injectables. High-resolution structural work defines how bivalent ligands antagonize the insulin receptor, guiding rational design of next‑generation antagonists for congenital hyperinsulinism. Large-scale genom
Summary
This week’s endocrinology literature highlights rapid therapeutic and precision-medicine advances: a phase 2b trial demonstrates clinically meaningful glycaemic lowering with a once-daily oral small-molecule GLP‑1 receptor agonist (elecoglipron), potentially expanding GLP‑1 access beyond injectables. High-resolution structural work defines how bivalent ligands antagonize the insulin receptor, guiding rational design of next‑generation antagonists for congenital hyperinsulinism. Large-scale genomic subanalysis from an RCT shows carriers of cardiomyopathy-associated variants derive outsized heart‑failure prevention benefit from dapagliflozin, supporting genotype-informed preventive strategies.
Selected Articles
1. Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with type 2 diabetes (SOLSTICE): a multicentre, phase 2b, randomised, placebo-controlled trial.
SOLSTICE, a multicentre phase 2b RCT (n=404 treated), showed once-daily oral elecoglipron produced clinically meaningful glycaemic reductions with a safety and tolerability profile consistent with GLP‑1 receptor agonists, supporting advancement to phase 3 development.
Impact: Demonstrates efficacy of an oral small-molecule GLP‑1RA, which could transform clinical access, adherence, and delivery compared with injectable therapies.
Clinical Implications: If phase 3 confirms efficacy and safety, elecoglipron could broaden GLP‑1RA use to patients unwilling/unable to use injectables, simplifying administration without food/fluid restrictions and altering treatment algorithms for T2D.
Key Findings
- Randomised, double-blind, placebo-controlled phase 2b trial across nine countries with 404 participants receiving study drug.
- Once-daily oral elecoglipron achieved clinically meaningful glycaemic reductions versus placebo.
- Safety and tolerability were consistent with the GLP‑1 receptor agonist class.
2. Structural basis of insulin receptor antagonism by bivalent site 1-site 2 ligands S961 and Ins-AC-S2.
High-resolution cryo-EM structures show that bivalent ligands S961 and Ins‑AC‑S2 stabilize an inactive insulin receptor conformation, explaining antagonism and revealing how module order determines agonism versus antagonism—insights that enable rational design of antagonists for congenital hyperinsulinism.
Impact: Provides mechanistic, structure-guided rationale for engineering safe and potent insulin receptor antagonists—a critical step toward therapies for rare endocrine disorders with limited options.
Clinical Implications: Enables structure-based optimization of insulin receptor antagonists; downstream steps include preclinical pharmacology and safety testing to develop therapies for congenital hyperinsulinism.
Key Findings
- Cryo-EM shows S961 and Ins‑AC‑S2 bind and stabilize an inactive insulin receptor conformation.
- Agonist vs antagonist activity is determined by the order of site‑1 and site‑2 binding modules in bivalent ligands.
- Distinct αCT and FnIII-2/insert domain interactions explain ligand-specific differences relevant to design.
3. Effects of SGLT2 inhibition on incident heart failure in carriers of cardiomyopathy-associated genetic variants.
Whole-exome sequencing within DECLARE‑TIMI 58 (n=12,685 sequenced) identified 121 carriers of pathogenic/likely pathogenic cardiomyopathy variants; dapagliflozin markedly reduced heart-failure hospitalization in carriers (HR 0.18) with large absolute risk reduction versus noncarriers, suggesting genotype‑dependent preventive benefit.
Impact: Provides actionable evidence that genetic subgroups within trial populations can have substantially different absolute and relative benefit from established drugs, pointing to genotype-guided preventive strategies.
Clinical Implications: Consider genotyping cardiomyopathy gene panels in high‑risk T2D patients to identify individuals who may gain outsized HF-preventive benefit from early SGLT2 inhibitor initiation; prospective genotype‑guided trials are warranted before routine adoption.
Key Findings
- Among 12,685 sequenced DECLARE participants, 121 carried pathogenic/likely pathogenic cardiomyopathy variants.
- Dapagliflozin reduced HHF more in carriers (HR 0.18) than in noncarriers (HR 0.70); Pinteraction=0.03.
- Absolute risk reduction of HHF was 13.0% in carriers versus 1.0% in noncarriers; benefit extended to carriers without prior HF.